China Healthcare Weekly (Dec.4)
This article summarized the updated news in China volume-based purchase policy, industry viewpoints, company news, and capital market review for...
226 Views
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
343 Views
HSCI Index Rebalance - Stock Connect Flows Coming Up
The Hang Seng Indexes Company Limited (HSIL) announced the results of its review of the Hang Seng Family of Indexes post market close on 14 August....
488 Views
HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities
Hang Seng Indexes Company (HSIL) reviews the constituents of the Hang Seng Composite Index (HSCI) on a half yearly basis in March and September...
769 Views
Akesobio (康方生物) IPO: Expect near Zero Allocation
Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...
578 Views